Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Inclusion Criteria: * Diagnosis of NF2 by National Institutes of Health (NIH) criteria * Age ≥ 16 years * Progressive VS growth during the previous 12 months. * WHO performance status \> or = 2 * Adequate bone marrow, liver and renal function. * For women of childbearing potential, no pregnancy or breast-feeding * Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions. * Willingness to provide informed consent Exclusion Criteria: * Inability to tolerate periodic MRI scans or gadolinium contrast. * Inability to tolerate periodic audiologic testing or to understand a language with established scoring for word recognition testing. * Inability to adequately perform volumetric measurement of at least 1 target lesionNote: Patients with cochlear or auditory brainstem implants may participate if a target lesion can be accurately assessed. * Radiation therapy for the target lesion in the 60 months preceding inclusion in the study. * Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug. * Immunization with attenuated live vaccines within one week of study entry or during study period. * Presence of a fungal infection requiring systemic antifungal treatment at enrollment * Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin. * Patients who have any severe and/or uncontrolled medical conditions. * Patients with a known hypersensitivity to everolimus or other types of rapamycin or to its excipients. * Patients unwilling to or unable to comply with the protocol